Key facts
- This page summarizes Eric Ostertag's Form 4 filing for Poseida Therapeutics, Inc..
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 10 Aug 2022, 18:13.
Eric Ostertag - 08 Aug 2022 Form 4 Insider Report for Poseida Therapeutics, Inc.
- Reporting relationship
- Executive Chairman, Director, 10%+ Owner
- Issuer ticker
- N/A
- Reported as of
- 08 Aug 2022
- Net transaction value
- +$500,000
- SEC form
- 4
- Accepted by SEC
- 10 Aug 2022, 18:13:51 UTC
- Prior SEC filing
- 05 Aug 2022
- Next SEC filing
- 17 Jan 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Harry J. Leonhardt, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Eric Ostertag filed Form 4 for Poseida Therapeutics, Inc. on 10 Aug 2022.
Change
- Previous filing in this sequence was filed on 05 Aug 2022.
- Current net transaction value: +$500,000.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
PSTX
transaction
Common Stock
Purchase
- Transaction value
- $500,000
- Shares
- +142,857
- Change %
- +21%
- Price
- $3.50
- Shares after
- 838,824
- Date
- 08 Aug 2022
- Ownership
- Direct
- Footnotes
- F1
PSTX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 3,659,503
- Date
- 08 Aug 2022
- Ownership
- See footnote
- Footnotes
- F2
PSTX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 3,358,455
- Date
- 08 Aug 2022
- Ownership
- See footnote
- Footnotes
- F3
PSTX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 580,292
- Date
- 08 Aug 2022
- Ownership
- See footnote
- Footnotes
- F4
PSTX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 961,445
- Date
- 08 Aug 2022
- Ownership
- See footnote
- Footnotes
- F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
This purchase is matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, with sales effected on August 3, 2022 pursuant to a Rule 10b5-1 trading plan established independently of the reporting person by Transposagen Biopharmaceuticals and in connection with a planned dissolution of Transposagen Biopharmaceuticals. The reporting person will disgorge the full amount of any recoverable profits to the Issuer.
Footnote F2
The shares are held in the name of the Eric Ostertag Living Trust dated March 30, 2016, of which the reporting person is the sole trustee.
Footnote F3
The shares are held in the name of Titan, LLC, which is owned by the Ostertag Descendents' Trust, of which the reporting person's minor daughter is the sole beneficiary. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
Footnote F4
The shares are held in the name of Twin Prime Investments, an entity wholly owned by the reporting person.
Footnote F5
The shares are held in the name of the Ostertag Family Trust dated March 30, 2016, of which the reporting person is a trustee.